NY-WISDOMTREE
WisdomTree, Inc. (NYSE: WT), a global financial innovator, today released monthly metrics for December 2022, including assets under management (AUM) and flow data by asset class.
Key Highlights:
- 2022 net inflows over $12 billion, nearly 16% firm-wide organic growth, with net inflows in 7 of its 8 major product categories during the year.
- Q4 net inflows over $5 billion, WisdomTree’s best quarter since 2015.
- Nine consecutive quarters of net inflows with record year-end AUM of nearly $82 billion.
- U.S. Equity products have generated net inflows in 30 of the prior 31 months, including $472 million in December and $3.3 billion of net inflows for the full year – a 14% pace of organic growth in 2022.
- WisdomTree announced nine new blockchain-enabled funds effective with the SEC, bringing the total to ten effective digital funds. These funds are in addition to the dollar and gold tokens that the firm is making available through WisdomTree PrimeTM.
As of December 31, 2022 |
AUM Rollforward
|
Annualized Flow Rate |
|||||||||||
|
MTD |
QTD |
YTD |
MTD |
QTD |
YTD |
|||||||
Beginning of Period Total AUM |
$80,734 |
|
$70,880 |
|
$77,451 |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|||
Total Net Flows |
|
|
|
|
|
|
|
|
|
|
|
||
U.S. Equity |
$472 |
|
$1,021 |
|
$3,344 |
|
22.3% |
|
19.3% |
|
14.0% |
||
International Dev. Mkt Equity |
($114) |
|
$40 |
|
$101 |
|
(12.6%) |
|
1.7% |
|
0.8% |
||
Emerging Market Equity |
($7) |
|
($53) |
|
$28 |
|
(0.9%) |
|
(2.8%) |
|
0.3% |
||
Fixed Income |
$703 |
|
$3,392 |
|
$11,300 |
|
56.9% |
|
115.1% |
|
259.6% |
||
Commodity & Currency |
$1,113 |
|
$796 |
|
($2,911) |
|
64.4% |
|
16.1% |
|
(11.8%) |
||
Alternatives |
$16 |
|
$12 |
|
$92 |
|
63.6% |
|
16.2% |
|
35.1% |
||
Cryptocurrency |
($7) |
|
($4) |
|
$36 |
|
(54.9%) |
|
(9.3%) |
|
10.1% |
||
Leveraged & Inverse |
($15) |
|
$59 |
|
$192 |
|
(10.4%) |
|
15.3% |
|
10.8% |
||
Total Net Flows |
$2,162 |
|
$5,264 |
|
$12,181 |
|
31.5% |
|
29.5% |
|
15.7% |
||
Market Move |
($910) |
|
$5,842 |
|
($7,646) |
|
|
|
|
|
|
||
Current Total AUM |
$81,986 |
|
$81,986 |
|
$81,986 |
|
|
|
|
|
|
||
Average Total AUM |
$81,238 |
|
$77,654 |
|
$76,992 |
|
|
|
|
|
|
||
Blended Total Average Fee Rate |
|
|
36 bps |
|
38 bps |
|
|
|
|
|
|
||
Source: ir.wisdomtree.com |
|||||||||||||
Please visit ir.wisdomtree.com for downloadable spreadsheets containing detailed AUM and flow data by asset class and fund broken out by daily, monthly, quarterly and annual timeframes.
About WisdomTree
WisdomTree is a global financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. We empower investors to shape their future and support financial professionals to better serve their clients and grow their businesses. WisdomTree is leveraging the latest financial infrastructure to create products that provide access, transparency and an enhanced user experience. Building on our heritage of innovation, we are also developing next-generation digital products and structures, including digital funds and tokenized assets, as well as our blockchain-native digital wallet, WisdomTree Prime™.
WisdomTree currently has approximately $83.8 billion in assets under management globally.
For more information about WisdomTree and WisdomTree Prime™, visit: https://www.wisdomtree.com.
Please visit us on Twitter at @WisdomTreeNews.
WisdomTree® is the marketing name for WisdomTree, Inc. and its subsidiaries worldwide.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain a number of “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our ability to successfully implement our digital assets strategy, including WisdomTree Prime™, and achieve its objectives. These forward-looking statements are based on WisdomTree’s management’s current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside WisdomTree’s management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements included in this release speak only as of the date of this release. WisdomTree does not undertake any obligation to update its forward-looking statements to reflect events or circumstances after the date of this release except as may be required by the federal securities laws.
Category: Business Update
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005026/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zetagen Therapeutics to Present Preliminary Results from Phase 2 Clinical Trial Targeting Metastatic Breast Cancer to Bone at the 2025 San Antonio Breast Cancer Symposium4.11.2025 16:04:00 CET | Press release
Complete Response in all treated lesions: Patients completing the study showed CR via the MD Anderson Criteria and RECIST v1.1 with no active tumor detected on MRIFirst-of-its-kind single intratumoral injection for MBC to the spineTreated lesions showed full bone regeneration with reconstitution of trabecular bone, and no skeletal related events; mean lesion defect volume decreased by 87.9% at day 180.Therapeutic spread extended to nearby non-treated lesions, also achieving complete response within the same vertebral body Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Single Intratumoral Drug Injection Yields Complete Response (CR) in Metastatic Breast Cancer (MBC) Bone Lesions”, has been accepted and will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 10, 2025. The abstract
ID5 Acquires TrueData, Combining Strengths to Create the Most Comprehensive Identity Solution for Digital Advertising4.11.2025 16:00:00 CET | Press release
Acquisition creates a global privacy-focused identity powerhouse and enhances value for partners through expanded capabilities ID5, the market-leading ID provider for digital advertising, has today announced the acquisition of TrueData, a top-tier US-based identity graph company. The deal represents a major step forward in ID5’s growth strategy, significantly strengthening its presence in the US and broadening the value it can deliver to partners worldwide. ID5, recognized as a global leader in the alternative ID space, has built a strong foothold in the US, where the majority of its clients and revenue originate. By bringing in TrueData’s graph, the company is expanding its operations in the US and strengthening its Adaptive Identity technology with new datasets and expertise. The combination of TrueData’s graph and expertise with the GDPR compliant ID5 Graph, and its scaled alternative ID creates a unique proposition in the market, connecting offline data with the largest online reac
Westlake Announces Proposed Offering of Senior Notes4.11.2025 15:15:00 CET | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of an underwritten public offering, subject to market and other conditions, of senior unsecured notes (the “Notes”) under its existing shelf registration statement. The timing of pricing and terms of the Notes are subject to market conditions and other factors. Westlake intends to use the net proceeds from the proposed public offering of the Notes to fund the repurchase of its outstanding 3.600% Senior Notes due 2026 (the “2026 Senior Notes”) pursuant to a concurrent cash tender offer (the “Tender Offer”) for any and all of the 2026 Senior Notes. Westlake anticipates using any remaining net proceeds to fund the purchase price of its pending acquisition of the global compounding solutions businesses of the ACI/Perplastic Group (the “ACI Acquisition”) and for general corporate purposes, including working capital management. The offering of the Notes is not contingent upon the successful completion of the Tende
Westlake Announces Cash Tender Offer4.11.2025 15:13:00 CET | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of a cash tender offer to purchase (the “Offer”) any and all of the outstanding 3.600% Senior Notes due 2026 (the “Notes”) as set forth in the table below. The tender offer is being made solely pursuant to the terms and conditions set forth in an Offer to Purchase, dated November 4, 2025 (the “Offer to Purchase”). Holders of the Notes are urged to carefully read the Offer to Purchase before making any decision with respect to the tender offer. The tender offer is not conditioned on any minimum amount of the Notes being tendered. Subject to applicable law, Westlake may amend, extend or terminate the tender offer in its sole discretion. Capitalized terms used but not defined in this announcement have the meanings given to them in the Offer to Purchase. Series of Notes CUSIP Numbers(1) Aggregate Principal Amount Outstanding U.S. Treasury Reference Security(2) Bloomberg Reference Page(2) Fixed Spread(3) 3.600% S
In-House Counsel Warn of Mounting Risks as Service of Process Volume Surges4.11.2025 15:00:00 CET | Press release
93% of in-house counsel say mass arbitration is increasing SOP risk and complexity59% report varying state requirements are driving compliance errors97% use AI for managing or analyzing SOP, yet 96% remain concerned about accuracy and speed The volume of service of process (SOP)—the legal procedure by which one party formally notifies another of a legal action—is surging across the U.S., amplifying operational pressure and compliance risk for in-house legal teams. This is according to a new nationwide study commissioned by CSC, industry-leading registered agent and compliance service provider. CSC surveyed 250 senior in-house counsel across the U.S. and found that rising SOP volume and growing concerns around data accuracy are intensifying both risk and workload pressure.1 Respondents cited data accuracy as a significant challenge to SOP management (61%), followed by rising SOP volume (56%). More than three-quarters (76%) said their departments are spending “too much” or “excessive” ti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom